<DOC>
	<DOCNO>NCT02011724</DOCNO>
	<brief_summary>The objective study demonstrate treatment Apligraf reduce venous leg ulcer ( VLU ) -related pain improves quality life ( QOL ) patient painful VLU .</brief_summary>
	<brief_title>A Study Of Pain And Quality Of Life Outcomes In Subjects With Single Painful Venous Leg Ulcer Treated With Apligraf®</brief_title>
	<detailed_description />
	<mesh_term>Ulcer</mesh_term>
	<mesh_term>Leg Ulcer</mesh_term>
	<mesh_term>Varicose Ulcer</mesh_term>
	<criteria>Subject minimum 18 year age . Subject read , understood , sign Institutional Review Board ( IRB ) approve Informed Consent Form ( ICF ) . Subject able willing follow study procedure instruction . Subject report moderate VLUrelated pain ( define ≥4 base maximum pain level precede 24 hour ) numeric rating scale ( NRS ) Week 2 Day 0 ) . Subject partial fullthickness VLU 160 cm2 136 month duration , , opinion Investigator , adequately respond conventional ulcer therapy . Female subject childbearing potential document negative urine pregnancy test . Subject ( male female ) agree use highly effective method contraception duration study . Subject 1 VLU . Female subject lactating . Subject significant severe non VLUrelated chronic pain , Investigator 's opinion , would impact subject 's ability evaluate VLUrelated pain . Subject nonVLUrelated chronic pain must stable pain medication regimen must , Investigator 's opinion , anticipate require new pain medication chronic pain condition course study . Subject willing discontinue use topical analgesic VLU ( topical anesthetic permit debridement ) . Subject arterial disease , determine anklebrachial index ( ABI ) , &lt; 0.65 . Subject receive investigational drug , device , biological/bioactive treatment within 30 day prior study enrollment . Subject schedule vascular intervention study extremity study . Subject biopsy confirm active malignancy VLU . Also , subject active malignancy VLU , exception squamous cell carcinoma basal cell carcinoma . Subject currently receive , anticipate receive , receive , time within 30 day prior Screening visit , topical corticosteroid VLU . Subject vasculitis , severe rheumatoid arthritis , collagen vascular disease . Subject sign symptom wound infection , cellulitis , osteomyelitis VLU . Subject VLU avascular wound bed . Subject VLU expose bone , tendon , fascia . Subject wound ( DFU , surgical , etc . ) limb VLU . Subject known hypersensitivity bovine collagen component Apligraf agarose ship medium . Subject previously treat Apligraf , cell tissuebased product VLU within 30 day Screening visit . Subject , opinion Investigator , history alcohol substance abuse within previous year could interfere study compliance ( eg , inability attend schedule study visit ) . Subject , opinion Investigator , reason list , able complete study per protocol .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2013</verification_date>
</DOC>